Our increased understanding of how key metabolic pathways are activated and regulated in
malignant cells has identified metabolic vulnerabilities of cancers. Translating this insight to …

Pancreatic cancer is a devastating disease with a low survival rate and limited treatment
options. Graphene quantum dots (GQDs) have recently become popular as a promising …

Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with high resistance to
therapies. Inflammatory and immunomodulatory signals co-exist in the pancreatic tumour …

Pancreatic ductal adenocarcinoma (PDAC) cells use glutamine (Gln) to support proliferation
and redox balance. Early attempts to inhibit Gln metabolism using glutaminase inhibitors …

KRAS mutations drive oncogenic alterations in numerous cancers, particularly in human
pancreatic ductal adenocarcinoma (PDAC). About 93% of PDACs have KRAS mutations …

The relevance of KRAS mutation alleles to clinical outcome remains inconclusive in
pancreatic adenocarcinoma (PDAC). We conducted a retrospective study of 803 patients …

Pancreatic cancer is characterized by a poor prognosis, with its five-year survival rate lower
than that of any other cancer type. Gemcitabine, a standard treatment for pancreatic cancer …

Effective detection of bio‐molecules relies on the precise design and preparation of
materials, particularly in laser desorption/ionization mass spectrometry (LDI‐MS). Despite …

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with poor
prognosis due to early metastasis, low diagnostic rates at early stages, and resistance to …

Surgical resection, when combined with chemotherapy, has been shown to significantly
improve the survival rate of patients with pancreatic ductal adenocarcinoma (PDAC) …